Radioactive bullet targets Hard-to-Treat breast cancer

NCT ID NCT07081555

Recruiting now Disease control Sponsor: Affibody Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, tolerable, and where it goes in the body. It is a first-in-human study, so the main goals are to check for side effects and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a radioactive drug called [177Lu]Lu-ABY-271 that targets HER2-positive cancer cells
What this could lead to: If it works, this could provide a new targeted treatment option for people with HER2-positive metastatic breast cancer that has stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 21 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2 + BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Akademiska Sjukhuset
RECRUITING

Uppsala, SE-751 85, Sweden
Karolinska University Hospital
RECRUITING

Stockholm, SE-17164, Sweden
Sahlgrenska University Hospital
RECRUITING

Gothenburg, S-413 45, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.